- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 500KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 83KB)
Risankizumab – March 2022
Risankizumab (Severe chronic plaque psoriasis): Injection 150 mg in 1 mL pre-filled pen, Injection 150 mg in 1 mL pre-filled syringe, Injection 75 mg in 0.83 mL pre-filled syringe; Skyrizi®
Last updated
1 July 2022